Published • loading... • Updated
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block ...
Investors allege ImmunityBio made false claims about Anktiva as a cancer vaccine, causing a 21% stock drop after FDA flagged misleading promotions.
- On Friday, law firms announced class action lawsuits against ImmunityBio, Inc. and its executives over alleged misleading statements regarding Anktiva, a bladder cancer drug. Investors have until May 26, 2026, to seek lead plaintiff status.
- A March 13 warning letter from the U.S. Food and Drug Administration to CEO Richard Adcock alleged promotional materials "misbrand Anktiva" and created a "misleading impression" that the drug could cure all cancer.
- According to the lawsuit, Executive Chairman and Global Scientific and Medical Officer Dr. Patrick Soon-Shiong materially overstated Anktiva's capabilities, falsely claiming the drug was a cancer vaccine and would keep patients "cancer-free for the long term."
- The litigation covers purchasers of ImmunityBio securities between January 19, 2026, and March 24, 2026. Investors may contact the Rosen Law Firm or Faruqi & Faruqi to join through contingency fee arrangements.
- Whistleblowers providing original information to the Securities Exchange Commission may receive rewards of up to 30% of successful recoveries. Investors need not serve as lead plaintiff to participate in potential future settlements.
Insights by Ground AI
48 Articles
48 Articles
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported ...
SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026.
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block ...
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (Nasdaq: IBRX) and certain of its executives. Investors who have lost money in their ImmunityBio investment should contact…
·Nebraska, United States
Read Full Article
Coverage Details
Total News Sources48
Leaning Left4Leaning Right3Center21Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
14%
C 75%
11%
Factuality
To view factuality data please Upgrade to Premium
